In this cohort of young breast cancer patients, 14 % were BRCA1 or BRCA2 P/LP variant carriers, which stands in accordance with other reports, including one published by the group, showing a 16.5 % BRCA mutation prevalence among 79 luminal breast cancer young patients (below 36 years).12 This evidence concerns the gene BRCA2 and breast carcinoma.